Follow The Filings

PFE Pfizer

Pfizer earnings company data as of 1:00 PM ET 10/23

  • 1 of 1 EPS beats
  • 2 Owners
  • Rank #64
  • Max 1.0%
  • Master 0.02%

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS 0.79 — —
Rev $15.86B — —
FY2026 Q2 4 Aug EPS 0.68 0.77 Beat +13.2%
Rev $14.40B $15.03B Beat +4.4%

Who owns this now

Largest portfolio weights among holders, up to 1.0% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

All holders
  1. Kentucky Trust Co. Add 0.95%
  2. Murphy Pohlad Add 0.54%

Insider trades

Open-market buys and sales by PFE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PFE insider trades
  • $3M bought by 3 insiders
  • $135K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Albert Bourla CEO
    Buy
    $1M 38,000 shares at $26.34 +9.7% to stake
    Traded Aug 12 Filed Aug 12
    ↗
  2. Jennifer B. Damico SVP & Controller
    Sale
    $83K 3,278 shares at $25.40 10% of stake
    Traded Aug 5 Filed Aug 6
    ↗
  3. Ronald E Blaylock Director
    Buy
    $999K 39,231 shares at $25.46 +142% to stake
    Traded Aug 5 Filed Aug 5
    ↗
  4. Mortimer J Buckley Director
    Buy
    $960K 37,632 shares at $25.52 New stake
    Traded Aug 5 Filed Aug 5
    ↗
  5. Jennifer B. Damico SVP & Controller
    Sale
    $51K 2,000 shares at $25.70 6% of stake
    Traded Jun 9 Filed Jun 10
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 share withholding for taxes.

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.